News

Published on 25 Mar 2024 on Zacks via Yahoo Finance

Should You Invest in the SPDR S&P Biotech ETF (XBI)?


Article preview image

If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the SPDR S&P Biotech ETF (XBI), a passively managed exchange traded fund launched on 01/31/2006.

While an excellent vehicle for long term investors, passively managed ETFs are a popular choice among institutional and retail investors due to their low costs, transparency, flexibility, and tax efficiency.

Additionally, sector ETFs offer convenient ways to gain low risk and diversified exposure to a broad group of companies in particular sectors. Healthcare - Biotech is one of the 16 broad Zacks sectors within the Zacks Industry classification. It is currently ranked 4, placing it in top 25%.

NASDAQ.IMGN price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
AbbVie: An Undervalued Giant

AbbVie Inc. (NYSE:ABBV) has made a decent recovery this year, jumping 11%. However, no good deed ...

GuruFocus.com via Yahoo Finance 27 Mar 2024

Is First Trust Mid Cap Core AlphaDEX ETF (FNX) a Strong ETF Right Now?

The First Trust Mid Cap Core AlphaDEX ETF (FNX) was launched on 05/08/2007, and is a smart beta e...

Zacks via Yahoo Finance 27 Mar 2024

AbbVie (ABBV) to Buy Landos to Strengthen Autoimmune Portfolio

AbbVie ABBV announced a definitive agreement to acquire Landos Biopharma LABP, which makes novel,...

Zacks via Yahoo Finance 26 Mar 2024

Why Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday? - Landos...

Monday, AbbVie Inc ABBV agreed to acquire Landos Biopharma Inc LABP for $20.42 per share, or appr...

Benzinga 25 Mar 2024

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, ...

Zacks via Yahoo Finance 25 Mar 2024

FDA grants full approval to AbbVie/ImmunoGen drug Elahere (NYSE:ABBV)

The FDA has granted full approval to AbbVie's (ABBV) ovarian cancer drug Elahere, which it acquir...

Seeking Alpha 22 Mar 2024

Stocks Rally as AI Craze Sweeps Across the World: Markets Wrap

(Bloomberg) -- The global stock rally powered ahead as Nvidia Corp.’s bullish outlook rekindled t...

Bloomberg via Yahoo Finance 22 Feb 2024

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

The SPDR S&P Biotech ETF (XBI) made its debut on 01/31/2006, and is a smart beta exchange traded ...

Zacks via Yahoo Finance 22 Feb 2024

11 Best Small-Cap Growth Stocks to Invest In

In this piece, we will take a look at the 11 best small-cap growth stocks to invest in. If you wa...

Insider Monkey via Yahoo Finance 22 Feb 2024

AbbVie (ABBV) Announces Appointment of New CEO Robert Michael

AbbVie ABBV announced that its current president and chief operating officer, Robert A. Michael, ...

Zacks via Yahoo Finance 21 Feb 2024